Amarin Corporation shares surged on Monday after the biopharmaceutical company’s fish oil capsule showed dramatic benefits in a clinical trial.
Amarin’s capsule, Vascepa, significantly reduced serious cardiovascular events compared to a placebo, according to Amarin’s trial results which looked at 8,179 statin-treated adults with elevated cardiovascular risk.
“We are delighted with these topline study results,” John Thero, president along with CEO of Amarin, said in a press Discharge. The company said the trial met the primary endpoint that has a 25 percent risk reduction.
Shares of Amarin were more than 300 percent higher in premarket trading Monday, around $12.40 a share. The stock had closed at $2.99 on Friday. Amarin was down more than 25 percent This specific year through Friday’s close.
Amarin will present the results at the 2018 Scientific Sessions of the American Heart Association in November.